November 25, 2022
Opdivo (nivolumab) was the best-selling drug in Japan on an NHI price basis in July-September, keeping its position for three consecutive quarters from January-March, according to a tally by IQVIA. Opdivo sales stood at 40.5 billion yen, rising 34.1% from...read more